BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma cash
Cash and short-term investments held at the end of each period.
BridgeBio Pharma's cash was $1.54B at Sep 30, 2026. For fiscal 2025 it was $587.48M, down 13.7% from the year before. The highest annual figure on record is $787.52M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $587.48M | -13.7% |
| FY2024 | Dec 31, 2024 | $681.10M | +81.2% |
| FY2023 | Dec 31, 2023 | $375.94M | -12.2% |
| FY2022 | Dec 31, 2022 | $428.27M | -45.6% |
| FY2021 | Dec 31, 2021 | $787.52M | +29.7% |
| FY2020 | Dec 31, 2020 | $607.09M | +11.2% |
| FY2019 | Dec 31, 2019 | $545.99M | +25.2% |
| FY2018 | Dec 31, 2018 | $436.09M | +374.0% |
| FY2017 | Dec 31, 2017 | $92.00M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.54B | +138.2% |
| Q2 FY2026 | Jun 30, 2026 | $720.16M | -4.9% |
| Q1 FY2026 | Mar 31, 2026 | $940.19M | +73.9% |
| Q4 FY2025 | Dec 31, 2025 | $587.48M | -13.7% |
| Q3 FY2025 | Sep 30, 2025 | $645.94M | +142.5% |
| Q2 FY2025 | Jun 30, 2025 | $756.89M | +69.0% |
| Q1 FY2025 | Mar 31, 2025 | $540.60M | +4.0% |
| Q4 FY2024 | Dec 31, 2024 | $681.10M | +81.2% |
| Q3 FY2024 | Sep 30, 2024 | $266.32M | -47.3% |
| Q2 FY2024 | Jun 30, 2024 | $447.77M | +34.3% |
| Q1 FY2024 | Mar 31, 2024 | $519.69M | +17.7% |
| Q4 FY2023 | Dec 31, 2023 | $375.94M | -12.2% |
| Q3 FY2023 | Sep 30, 2023 | $505.21M | -9.5% |
| Q2 FY2023 | Jun 30, 2023 | $333.31M | -51.6% |
| Q1 FY2023 | Mar 31, 2023 | $441.49M | -30.3% |
| Q4 FY2022 | Dec 31, 2022 | $428.27M | -45.6% |
| Q3 FY2022 | Sep 30, 2022 | $558.32M | -6.9% |
| Q2 FY2022 | Jun 30, 2022 | $688.56M | -17.8% |
| Q1 FY2022 | Mar 31, 2022 | $633.45M | -31.1% |
| Q4 FY2021 | Dec 31, 2021 | $787.52M | +29.7% |
| Q3 FY2021 | Sep 30, 2021 | $599.61M | -15.6% |
| Q2 FY2021 | Jun 30, 2021 | $837.66M | -0.4% |
| Q1 FY2021 | Mar 31, 2021 | $919.12M | +1.5% |
| Q4 FY2020 | Dec 31, 2020 | $607.09M | +11.2% |
| Q3 FY2020 | Sep 30, 2020 | $710.68M | +32.6% |
| Q2 FY2020 | Jun 30, 2020 | $840.94M | +186.2% |
| Q1 FY2020 | Mar 31, 2020 | $905.18M | +142.7% |
| Q4 FY2019 | Dec 31, 2019 | $545.99M | +25.2% |
| Q3 FY2019 | Sep 30, 2019 | $536.05M | +153.2% |
| Q2 FY2019 | Jun 30, 2019 | $293.80M | +219.4% |
| Q1 FY2019 | Mar 31, 2019 | $373.03M | – |
| Q4 FY2018 | Dec 31, 2018 | $436.09M | – |
| Q3 FY2018 | Sep 30, 2018 | $211.73M | – |
| Q4 FY2017 | Dec 31, 2017 | $92.00M | – |
See a number that looks wrong?